Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies tha
BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
06:30am, Wednesday, 09'th Jun 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies tha
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2021 Results - Earnings Call Transcript
02:09pm, Monday, 24'th May 2021
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2021 Results - Earnings Call Transcript
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
06:30am, Monday, 24'th May 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies tha
BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021
06:30am, Tuesday, 18'th May 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies tha
BiomX: Rapidly Advancing Phage Therapeutics With Multiple Upcoming Catalysts
12:35pm, Wednesday, 21'st Apr 2021
Using its proprietary BOLT phage therapy platform, BiomX is developing natural and engineered bacteriophage (Phage) therapies to treat chronic diseases and cancer. On March 31st announced 2 phage ther
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q4 2020 Results - Earnings Call Transcript
11:08am, Wednesday, 31'st Mar 2021
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q4 2020 Results - Earnings Call Transcript
BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
06:30am, Wednesday, 31'st Mar 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies tha
BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021
06:30am, Wednesday, 24'th Mar 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing natural and engineered phage therapies that targ
PHGE Stock Price Increases Over 8% Pre-Market: Why It Happened
08:35am, Tuesday, 02'nd Mar 2021
The stock price of BiomX Inc. (NYSEAMERICAN: PHGE) is trading at over 8% pre-market. This is why it happened.
BiomX to Present at Upcoming March Investor Conferences
07:00am, Monday, 01'st Mar 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today a
BiomX Inc.: Clinical Stage Phage Therapeutics Company Looks Promising
11:08am, Monday, 22'nd Feb 2021
BiomX is a clinical-stage microbiome company using its novel BOLT phage therapy platform to develop customized phage therapies to treat chronic diseases ranging from IBC, colorectal cancer, Cystic Fib
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announ
BiomX to Present at Upcoming January Investor Conferences
06:30am, Monday, 04'th Jan 2021
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announce
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announce
